216 related articles for article (PubMed ID: 7590471)
1. Conservative management of chemotherapeutic-induced thrombocytopenia in women with gynecologic cancers.
Fanning J; Hilgers RD; Murray KP; Bolt K; Aughenbaugh DM
Gynecol Oncol; 1995 Nov; 59(2):191-3. PubMed ID: 7590471
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy.
Cantor SB; Elting LS; Hudson DV; Rubenstein EB
Cancer; 2003 Jun; 97(12):3099-106. PubMed ID: 12784347
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Navarro JT; Hernández JA; Ribera JM; Sancho JM; Oriol A; Pujol M; Millá F; Feliu E
Haematologica; 1998 Nov; 83(11):998-1000. PubMed ID: 9864920
[TBL] [Abstract][Full Text] [Related]
4. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
Rebulla P; Finazzi G; Marangoni F; Avvisati G; Gugliotta L; Tognoni G; Barbui T; Mandelli F; Sirchia G
N Engl J Med; 1997 Dec; 337(26):1870-5. PubMed ID: 9407153
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer.
Goldberg GL; Gibbon DG; Smith HO; DeVictoria C; Runowicz CD; Burns ER
J Clin Oncol; 1994 Nov; 12(11):2317-20. PubMed ID: 7964946
[TBL] [Abstract][Full Text] [Related]
6. Current practice and future directions for optimization of platelet transfusions in patients with severe therapy-induced cytopenia.
Apelseth TO; Hervig T; Bruserud O
Blood Rev; 2011 May; 25(3):113-22. PubMed ID: 21316823
[TBL] [Abstract][Full Text] [Related]
7. Platelet utilization and the transfusion trigger: a prospective analysis.
Greeno E; McCullough J; Weisdorf D
Transfusion; 2007 Feb; 47(2):201-5. PubMed ID: 17302764
[TBL] [Abstract][Full Text] [Related]
8. An audit of platelet transfusion within the Wellington Cancer Centre.
Buhrkuhl DC; Karlsson MK; Carter JM
Intern Med J; 2012 Jan; 42(1):65-70. PubMed ID: 21040321
[TBL] [Abstract][Full Text] [Related]
9. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design.
Tinmouth A; Tannock IF; Crump M; Tomlinson G; Brandwein J; Minden M; Sutton D
Transfusion; 2004 Dec; 44(12):1711-9. PubMed ID: 15584985
[TBL] [Abstract][Full Text] [Related]
10. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
[TBL] [Abstract][Full Text] [Related]
11. The clinical development of recombinant human interleukin 11 (NEUMEGA rhIL-11 growth factor).
Kaye JA
Stem Cells; 1996; 14 Suppl 1():256-60. PubMed ID: 11012229
[TBL] [Abstract][Full Text] [Related]
12. Thrombocytopenia and platelet transfusions in patients with cancer.
Valent J; Schiffer CA
Cancer Treat Res; 2011; 157():251-65. PubMed ID: 21052961
[TBL] [Abstract][Full Text] [Related]
13. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
14. Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 x 10(9) or 20 x 10(9) per L.
Nevo S; Fuller AK; Zahurak ML; Hartley E; Borinsky ME; Vogelsang GB
Transfusion; 2007 Sep; 47(9):1700-9. PubMed ID: 17725737
[TBL] [Abstract][Full Text] [Related]
15. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation.
Wandt H; Schaefer-Eckart K; Frank M; Birkmann J; Wilhelm M
Bone Marrow Transplant; 2006 Feb; 37(4):387-92. PubMed ID: 16400342
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia].
Sun XF; Guan ZZ; Huang H; Zhou QH; Yi C; Zhang LJ; Zhu J; Li R; Zhou J; Zhang M; Guo Y
Ai Zheng; 2002 Aug; 21(8):892-5. PubMed ID: 12478901
[TBL] [Abstract][Full Text] [Related]
17. [Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia].
Wang XY; Feng FY; Song ST; Wang HQ; Zhang MH; Liu J; Liu XY; Xu LG; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):373-6. PubMed ID: 16117903
[TBL] [Abstract][Full Text] [Related]
18. Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses.
Arnold DM; Crowther MA; Cook RJ; Sigouin C; Heddle NM; Molnar L; Cook DJ
Transfusion; 2006 Aug; 46(8):1286-91. PubMed ID: 16934061
[TBL] [Abstract][Full Text] [Related]
19. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature.
Hopkins CK; Goldfinger D
Transfusion; 2008 Oct; 48(10):2128-32. PubMed ID: 18657085
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.
Vadhan-Raj S; Verschraegen CF; Bueso-Ramos C; Broxmeyer HE; Kudelkà AP; Freedman RS; Edwards CL; Gershenson D; Jones D; Ashby M; Kavanagh JJ
Ann Intern Med; 2000 Mar; 132(5):364-8. PubMed ID: 10691586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
